DBV Technologies (NASDAQ:DBVT) Shares Down 6.9% – Should You Sell?

DBV Technologies S.A. (NASDAQ:DBVT)’s stock price traded down 6.9% on Wednesday . The stock traded as low as $16.30 and last traded at $16.15. 49,508 shares traded hands during trading, a decline of 83% from the average daily volume of 296,577 shares. The stock had previously closed at $17.35.

Wall Street Analyst Weigh In

Several research firms have recently commented on DBVT. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of DBV Technologies in a research note on Monday, June 29th. Wall Street Zen lowered DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright reaffirmed a “buy” rating on shares of DBV Technologies in a report on Tuesday, June 30th. Finally, Citizens Jmp upped their target price on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research report on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $48.50.

DBV Technologies Stock Down 3.3%

The company has a market cap of $993.58 million, a price-to-earnings ratio of -3.76 and a beta of -0.95. The company’s 50-day moving average is $17.84 and its 200 day moving average is $19.72.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%.The firm had revenue of $0.90 million during the quarter, compared to analyst estimates of $1.11 million. Analysts predict that DBV Technologies S.A. will post -0.38 EPS for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

Hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC grew its holdings in DBV Technologies by 38.4% in the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after purchasing an additional 744 shares during the period. Truvestments Capital LLC lifted its position in shares of DBV Technologies by 71.3% during the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after buying an additional 1,620 shares in the last quarter. Allworth Financial LP purchased a new position in shares of DBV Technologies during the 4th quarter valued at approximately $32,000. Royal Bank of Canada acquired a new stake in DBV Technologies in the 4th quarter valued at $34,000. Finally, Persistent Asset Partners Ltd acquired a new stake in DBV Technologies in the 4th quarter valued at $115,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.